Atlas Trials

Recurrent Waldenstrom Macroglobulinemia

12 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Recurrent Waldenstrom Macroglobulinemia

RecordFirmDate
Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia (NCT03506373)Mayo Clinic2018-08-14
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation (NCT03246906)Fred Hutchinson Cancer Center2017-09-11
Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma (NCT03147885)Barbara Ann Karmanos Cancer Institute2017-06-20
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NCT02950220)Kami Maddocks2017-01-12
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas (NCT02332980)Mayo Clinic2015-02-19
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma (NCT01381692)National Cancer Institute (NCI)2011-07-20
Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (NCT01198067)M.D. Anderson Cancer Center2010-10-06

Track Recurrent Waldenstrom Macroglobulinemia automatically

Every clearance here is in the API, with alerts when new ones post.